Immunocore Holdings Ltd (IMCR)vsMerck & Company Inc (MRK)
IMCR
Immunocore Holdings Ltd
$32.60
-2.92%
HEALTHCARE · Cap: $1.82B
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 15353% more annual revenue ($66.57B vs $430.77M). MRK leads profitability with a 4.8% profit margin vs -4.2%. IMCR earns a higher WallStSmart Score of 37/100 (F).
IMCR
Hold37
out of 100
Grade: F
MRK
Hold36
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for IMCR.
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Earnings expanding 150.0% YoY
18.3% revenue growth
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
Elevated debt levels
ROE of -7.1% — below average capital efficiency
Negative free cash flow — burning cash
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : IMCR
The strongest argument for IMCR centers on EPS Growth, Revenue Growth. Revenue growth of 18.3% demonstrates continued momentum.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bear Case : IMCR
The primary concerns for IMCR are Market Cap, Debt/Equity, Return on Equity.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Key Dynamics to Monitor
IMCR profiles as a growth stock while MRK is a value play — different risk/reward profiles.
IMCR carries more volatility with a beta of 0.74 — expect wider price swings.
IMCR is growing revenue faster at 18.3% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
IMCR scores higher overall (37/100 vs 36/100) and 18.3% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Immunocore Holdings Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Immunocore Holdings Limited, an advanced stage biotechnology company, develops immunotherapies for the treatment of cancer, infectious and autoimmune diseases. The company is headquartered in Abingdon, the United Kingdom.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?